Ucenprubart
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LY3454738 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Ucenprubart (LY3454738) is a monoclonal antibody that acts as an agonist at CD200R1 and is developed by Eli Lilly and Company for atopic dermatitis and other autoimmune diseases.[1][2][3][4]
References[edit]
- ^ Metz, Martin; Maurer, Marcus (12 February 2021). "Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?". Allergologie Select. 5: 89–95. doi:10.5414/ALX02204E. ISSN 2512-8957. PMC 7890936. PMID 33615122.
- ^ Metz, Martin; Kolkhir, Pavel; Altrichter, Sabine; Siebenhaar, Frank; Levi-Schaffer, Francesca; Youngblood, Bradford A.; Church, Martin K.; Maurer, Marcus (22 August 2023). "Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases". Allergy. 79 (1): 37–51. doi:10.1111/all.15850. PMID 37605867. S2CID 261063967.
- ^ Maurer, Marcus; Khan, David A.; Elieh Ali Komi, Daniel; Kaplan, Allen P. (1 March 2021). "Biologics for the Use in Chronic Spontaneous Urticaria: When and Which". The Journal of Allergy and Clinical Immunology: In Practice. 9 (3): 1067–1078. doi:10.1016/j.jaip.2020.11.043. ISSN 2213-2198. PMID 33685605. S2CID 232159087.
- ^ "Lilly.com | Eli Lilly and Company". www.lilly.com. Retrieved 24 November 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |